Due to temporary supply chain issues, 12 subjects in an ongoing trial who were receiving the Brixadi formulation of extended-release buprenorphine were switched to the Sublocade formulation for one month, then later resumed Brixadi. In this article, these patients – who are uniquely able to compare their experiences with these two medications – report on the perceived benefits, drawbacks, and differences between each formulation.